Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

19

Revenue 2017

Keytruda

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Keytruda was produced by Merck & Co..

HTA guidance from NICE, the SMC and the AWMSG

Specifically, NICE’s recommends Keytruda as an option with chemotherapy for neoadjuvant, and alone as adjuvant treatment after surgery for patients with early triple-negative or locally advanced breast cancer.

Merck’s Keytruda receives NICE recommendation as breast cancer treatment option

Merck’s Keytruda receives NICE recommendation as breast cancer treatment option Specifically, NICE’s recommends Keytruda as an option with chemotherapy for neoadjuvant, and alone as adjuvant treatment after surgery for patients with early triple-negative or locally advanced breast cancer. ... There was also a significantly higher

Merck and Moderna to jointly develop personalised cancer vaccine in $250m deal

Merck and Moderna to jointly develop personalised cancer vaccine in $250m deal Keytruda was selected as the comparator in the trial because it is considered a standard-of-care for high-risk melanoma patients, the companies outlined. ... mRNA-4157 as an investigational personalised cancer treatment used in combination with Keytruda.

Merck bags NICE recommendation for renal cell carcinoma adjuvant treatment

Merck bags NICE recommendation for renal cell carcinoma adjuvant treatment An analysis of the study found that Keytruda increased disease-free survival at 24 months compared with placebo, the primary efficacy endpoint of the trial. ... Overall survival at 24 months was also higher with Keytruda compared with placebo, although

AstraZeneca and Daiichi Sankyo announce results for lung cancer therapy

AstraZeneca and Daiichi Sankyo announce results for lung cancer therapy Initial results for the combination therapy – with Merck’s Keytruda – show an overall response rate of 37% in patients with non-small cell lung cancer. ... therapies. The data presented demonstrated an overall response rate of 37% when Dato-DXd was

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Thrive Agency

We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...

Latest intelligence

Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....
Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...